High excision repair cross-complementation group 1 expression is associated with favorable prognostic factors in breast cancer

Kim,Dong  Hyun; Lee,Hyunjoo; Kim,Dong‑Hoon; Chae,Seoung  Wan; Sohn,Jin  Hee; Kim,Kyungeun; Do,Sung‑Im

doi:10.3892/ol.2017.6737

High excision repair cross-complementation group 1 expression is associated with favorable prognostic factors in breast cancer

Authors:
- Dong Hyun Kim
- Hyunjoo Lee
- Dong‑Hoon Kim
- Seoung Wan Chae
- Jin Hee Sohn
- Kyungeun Kim
- Sung‑Im Do
View Affiliations

Affiliations: Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 110‑746, Republic of Korea
Published online on: August 9, 2017 https://doi.org/10.3892/ol.2017.6737
Pages: 4995-5003

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Distortion of DNA can inhibit transcription and replication, resulting in cell death. The nucleotide excision repair (NER) pathway recognizes and repairs DNA adducts. Excision repair cross‑complementation group 1 (ERCC1) is a nuclease that serves a vital role in the NER pathway. Few studies have investigated ERCC1 expression in breast cancer. The aim of the present study was to analyze the association between clinicopathological features and ERCC1 expression in breast cancer. ERCC1 expression was studied in 224 invasive ductal carcinomas by immunohistochemical staining. ERCC1 expression was analyzed as an immunoreactive score, and classified into low and high expression groups. The association between immunohistochemical parameters and clinicopathological features was evaluated. High expression of ERCC1 was observed in 33 cases (14.7%) and was statistically associated with lower T stage (P=0.005), lower tumor size (P=0.001), no lymph node metastasis (P=0.044) and no lymphovascular invasion (LVI; P=0.004). Additionally, high ERCC1 expression was associated with a positive estrogen receptor (ER) (P=0.006) and progesterone receptor (PR) (P=0.001) expression status. Non‑triple‑negative breast carcinoma occurred more frequently in the high expression group (97%) than the low expression group; however, the difference was not statistically significant (P=0.056). Overall and disease‑free survival were also not significantly different between the two groups (P=0.989 and P=0.215, respectively). In conclusion, high ERCC1 expression is statistically associated with lower T stage, smaller tumor size, no lymph node metastasis, no LVI, and positive ER and PR expression. This suggests that ERCC1 is associated with favorable prognostic parameters in breast cancer.

View Figures

View References

1	Li CI, Anderson BO, Daling JR and Moe RE: Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA. 289:1421–1424. 2003. View Article : Google Scholar : PubMed/NCBI
2	Li CI, Uribe DJ and Daling JR: Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 93:1046–1052. 2005. View Article : Google Scholar : PubMed/NCBI
3	Subramaniam S, Bhoo-Pathy N, Taib NA, Tan GH, See MH, Jamaris S, Ho GF, Looi LM and Yip CH: Breast cancer outcomes as defined by the estrogen receptor, progesterone receptor and human growth factor receptor-2 in a multi-ethnic Asian country. World J Surg. 39:2450–2458. 2015. View Article : Google Scholar : PubMed/NCBI
4	Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
5	Schnitt SJ: Classification and prognosis of invasive breast cancer: From morphology to molecular taxonomy. Mod Pathol. 23:(Suppl 2). S60–S64. 2010. View Article : Google Scholar : PubMed/NCBI
6	Engstrom MJ, Opdahl S, Hagen AI, Romundstad PR, Akslen LA, Haugen OA, Vatten LJ and Bofin AM: Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat. 140:463–473. 2013. View Article : Google Scholar : PubMed/NCBI
7	Parise CA and Caggiano V: Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers. J Cancer Epidemiol. 2014:4692512014. View Article : Google Scholar : PubMed/NCBI
8	Gajria D and Chandarlapaty S: HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 11:263–275. 2011. View Article : Google Scholar : PubMed/NCBI
9	Hudis CA and Gianni L: Triple-negative breast cancer: An unmet medical need. Oncologist. 16:(Suppl 1). S1–S11. 2011. View Article : Google Scholar
10	Kirschner K and Melton DW: Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res. 30:3223–3232. 2010.PubMed/NCBI
11	McNeil EM and Melton DW: DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy. Nucleic Acids Res. 40:9990–10004. 2012. View Article : Google Scholar : PubMed/NCBI
12	Sidoni A, Cartaginese F, Colozza M, Gori S and Crinó L: ERCC1 expression in triple negative breast carcinoma: The paradox revisited. Breast Cancer Res Treat. 111:569–570. 2008. View Article : Google Scholar : PubMed/NCBI
13	Ozkan C, Gumuskaya B, Yaman S, Aksoy S, Guler G and Altundag K: ERCC1 expression in triple negative breast cancer. J BUON. 17:271–276. 2012.PubMed/NCBI
14	Goyal S, Parikh RR, Green C, Schiff D, Moran MS, Yang Q and Haffty BG: Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 76:679–684. 2010. View Article : Google Scholar : PubMed/NCBI
15	Gerhard R, Carvalho A, Carneiro V, Bento RS, Uemura G, Gomes M, Albergaria A and Schmitt F: Clinicopathological significance of ERCC1 expression in breast cancer. Pathol Res Pract. 209:331–336. 2013. View Article : Google Scholar : PubMed/NCBI
16	Kim D, Jung W and Koo JS: The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. J Korean Med Sci. 26:352–359. 2011. View Article : Google Scholar : PubMed/NCBI
17	Edge SB: American Joint Committee On Cancer, AJCC Cancer Staging Manual. 8th. Springer; New York, NY: 2010
18	O'Malley FP and Pinder SE: Breast pathology, Churchill Livingstone. Elsevier; Edinburgh: 2006, View Article : Google Scholar
19	Nadji M, Gomez-Fernandez C, Ganjei-Azar P and Morales AR: Immunohistochemistry of estrogen and progesterone receptors reconsidered: Experience with 5,993 breast cancers. Am J Clin Pathol. 123:21–27. 2005. View Article : Google Scholar : PubMed/NCBI
20	Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 31:3997–4013. 2013. View Article : Google Scholar : PubMed/NCBI
21	Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
22	Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584. 2007. View Article : Google Scholar : PubMed/NCBI
23	Fu JM, Zhou J, Xie JS and Li H: Effect of neoadjuvant chemotherapy on ERCC1 gene expression in breast cancer. Nan Fang Yi Ke Da Xue Xue Bao. 28:603–605. 2008.(In Chinese). PubMed/NCBI
24	Metro G, Zheng Z, Fabi A, Schell M, Antoniani B, Mottolese M, Monteiro AN, Vici P, Lara Rivera S, Boulware D, et al: In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. Cancer Invest. 28:172–180. 2010. View Article : Google Scholar : PubMed/NCBI
25	Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, et al: ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer. 60:401–407. 2008. View Article : Google Scholar : PubMed/NCBI
26	Seyhan EC, Altin S, Cetinkaya E, Sökücü S, Abali H, Buyukpinarbasili N and Fener N: Prognostic significance of ERCC1 expression in resected non small cell lung carcinoma. Ann Thorac Cardiovasc Surg. 17:110–117. 2011. View Article : Google Scholar : PubMed/NCBI
27	Wang J, Zhou XQ, Li JY, Cheng JF, Zeng XN, Li X and Liu P: Prognostic significance of ERCC1 expression in postoperative patients with gastric cancer. Chin J Cancer Res. 26:323–330. 2014.PubMed/NCBI
28	Han W, Kim KY, Yang SJ, Noh DY, Kang D and Kwack K: SNP-SNP interactions between DNA repair genes were associated with breast cancer risk in a Korean population. Cancer. 118:594–602. 2012. View Article : Google Scholar : PubMed/NCBI
29	Mojgan H, Massoud H and Ahmad E: ERCC1 intron 1 was associated with breast cancer risk. Arch Med Sci. 8:655–658. 2012. View Article : Google Scholar : PubMed/NCBI
30	Mo J, Xia Y, Ning Z, Wade TJ and Mumford JL: Elevated ERCC1 gene expression in blood cells associated with exposure to arsenic from drinking water in Inner Mongolia. Anticancer Res. 29:3253–3259. 2009.PubMed/NCBI